{"groups":[{"description":"Participants received 5 milligrams (mg) of fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"FG000","title":"Fruquintinib + Best Supportive Care (BSC) Group"},{"description":"Participants received placebo matched to fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"FG001","title":"Placebo + BSC Group"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"411"},{"groupId":"FG001","numSubjects":"203"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"8"}],"type":"Withdrawal of consent"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"0"}],"type":"Radiological Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"14"}],"type":"Sponsor Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"4"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"461"},{"groupId":"FG001","numSubjects":"230"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"456"},{"groupId":"FG001","numSubjects":"230"}],"comment":"The Safety population (SP) included all randomized participants who received at least 1 dose of study drug.","type":"Safety Population (SP)"},{"achievements":[{"groupId":"FG000","numSubjects":"329"},{"groupId":"FG001","numSubjects":"2"}],"comment":"The Pharmacokinetic (PK) population included all participants who received at least 1 dose of study drug and had at least 1 post dose PK sample collected and analyzed.","type":"Pharmacokinetic (PK) Population"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"461"},{"groupId":"FG001","numSubjects":"230"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 691 participants were randomized and enrolled in this study.","recruitmentDetails":"The study was conducted at 124 study sites in the United States, Europe region, Japan, and Australia."}